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The hypothesis that bone
turnover influences FGF23
secretion
To the Editor: Fibroblast growth factor 23 (FGF23) regulates
serum phosphate (Pi) levels. Isakova et al.1 commented on
a blueprint for randomized trials targeting phosphorus
metabolism in chronic kidney disease. In this review, Isakova
et al. revealed that Pi levels were normal to high in secondary
syndromes of FGF23 excess, such as kidney disease; however,
the levels were low in ‘primary’ syndromes of FGF23 excess,
such as the hereditary diseases (X-linked hypophosphatemia,
autosomal dominant hypophosphatemic rickets, autosomal
recessive hypophosphatemic rickets), and tumor-induced
osteomalacia. With decrease in renal function, the serum
FGF23 level is elevated; however, the phosphorus excretion
decreases. Osteitis ﬁbrosa progresses at the same time. FGF23
was secreted by osteocytes.2 Therefore, we drew up the
hypothesis that bone turnover inﬂuences FGF23 secretion.
We had reported previously the response of phosphorus load
to osteoprotegerin (OPG) knockout (KO) mice (Figure 1).
FGF-23 expression was signiﬁcantly increased by a high-
phosphate diet in wild-type (WT) mice, but not in OPG KO
mice. NaPi2a messenger RNA expression in kidney was
suppressed in WT mice receiving a high-phosphate diet, but
suppression was less marked in OPG KO mice. Therefore,
OPG may have a key role in mediating the response of FGF-
23 to an oral phosphate load in bone cells.3 When we evaluate
the metabolism of FGF23, it is necessary to consider the
structural change in the osteitis ﬁbrosa.
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The Authors Reply: We agree with Ohkido et al.1 that
osteocytes likely have a critical role in ﬁbroblast growth
factor (FGF)23 regulation in chronic kidney disease (CKD).
In addition to the supportive ﬁndings from their animal
studies outlined in ‘The hypothesis that bone turnover
inﬂuences FGF23 secretion,’ recent human studies have
shown that FGF23 expression in bone is already elevated in
the early stages of CKD.2 Moreover, emerging data on the
structure and function of osteocytes, their dendritic processes,
and surrounding capillary networks have provided further
support for the existence of a bone–kidney axis.3 Future
explorations of this hypothesis are likely to yield signiﬁcant
new insights into bone physiology and regulation of phos-
phorus metabolism and, ideally, the discovery of novel
therapeutic targets for various bone and mineral illnesses.
However, assessments of bone disease with bone biopsies in
the large-scale randomized trials we propose would increase
the complexity of trial design and diminish feasibility, and
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Figure 1 |Percentage tubular reabsorption of phosphate (%TRP). Percentage TRP levels of the wild-type (WT)/high-phosphate diet
group are significantly lower than those of the WT/normal-diet group. In the osteoprotegerin/high-phosphate (OPG KO/high-P) group, they
are significantly lower than in the OPG KO/normal-diet group, but the reduction rate is significantly lower in OPG KO mice than in WT mice.
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